<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-131364" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cannabis Versus Opioids for Pain</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khalid</surname>
            <given-names>Noman</given-names>
          </name>
          <aff>Shaikh Zayed Hospital Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Abhishek</given-names>
          </name>
          <aff>All India Institute of Medical Sciences, New Delhi</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noman Khalid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abhishek Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-131364.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Opioids are commonly prescribed to treat and manage chronic and severe pain; however, their potential for abuse and dependency is a concern. Chronic and unrelenting pain can have significant psychological, physical, and emotional stress on individuals. Several strategies are employed to mitigate intractable pain that does not respond to nonsteroidal anti-inflammatory drugs (NSAIDs), with opioids being widely recognized as the cornerstone of pain management protocols. In recent years, there has been emerging and growing evidence indicating the potential efficacy of cannabinoids in managing chronic pain. This activity offers an overview of the signs and symptoms of adverse events and the crucial aspects of monitoring, intervention, and other pertinent considerations in opioid therapy and cannabinoids for patients with chronic pain. These key points are indispensable for fostering effective collaboration among interprofessional team members responsible for patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with chronic pain and provide education regarding the limitations of opioids and cannabinoids, including potential incomplete pain relief, mechanisms of action, and associated risks and adverse effects, emphasizing the importance of multimodal treatment approaches.</p></list-item><list-item><p>Elucidate the signs and symptoms of opioid-related drug abuse by identifying behavioral changes in individuals, such as social withdrawal, increased secrecy, or sudden financial difficulties, in order to ensure the optimal effectiveness and safety of opioid and cannabinoid treatment.</p></list-item><list-item><p>Identify and navigate legal issues associated with cannabis use by thoroughly understanding the potential benefits, risks, and State regulations governing its use for both medical and recreational purposes.</p></list-item><list-item><p>Assess patients' pain levels, treatment response, functional outcomes, and potential adverse effects of opioid and cannabinoid therapy, ensuring ongoing monitoring and optimization of pain management strategies.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131364&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131364">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-131364.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>In the human body, pain is an inherent alarm system that activates when there is actual or potential damage, directing an individual's attention toward the issue.<xref ref-type="bibr" rid="article-131364.r1">[1]</xref><xref ref-type="bibr" rid="article-131364.r2">[2]</xref><xref ref-type="bibr" rid="article-131364.r3">[3]</xref> Pain is a frequently cited reason for seeking healthcare or medical assistance. Pain encompasses various elements, including nociception, the perception of pain, suffering, and pain behaviors. Although pain is a fundamental mechanism, it can become burdensome when it persists for an extended period, leading to suffering and pain-related behaviors. Chronic and unrelenting pain can cause psychological, physical, and emotional distress, adding further strain to individuals.<xref ref-type="bibr" rid="article-131364.r4">[4]</xref></p>
        <p>The search for an ideal pain relief medication has been an ongoing endeavor since ancient times, as certain types of pain still lack definitive treatment options. Several strategies have been developed to address intractable pain that does not respond to nonsteroidal anti-inflammatory drugs (NSAIDs), with opioids being the mainstay in many pain management protocols.&#x000a0;In recent years, there has been growing and promising evidence&#x000a0;suggesting the potential effectiveness of cannabinoids in the management of chronic pain.<xref ref-type="bibr" rid="article-131364.r5">[5]</xref><xref ref-type="bibr" rid="article-131364.r6">[6]</xref></p>
      </sec>
      <sec id="article-131364.s3" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Opioids</bold>
</p>
        <p>Endogenous opioids are produced in the body physiologically, which help in pain modulation. These endogenous opioids act on presynaptic &#x003bc;-, &#x003ba;-, and &#x003b4;-opioid receptors, reducing excitatory neurotransmitters' release. They achieve this by decreasing calcium influx in the presynaptic membrane and increasing potassium influx in the postsynaptic membrane.<xref ref-type="bibr" rid="article-131364.r7">[7]</xref><xref ref-type="bibr" rid="article-131364.r8">[8]</xref>&#x000a0;Pharmacologists utilize the specific characteristics of opioid receptors to develop and administer exogenous opioids for pain management. These exogenous opioids have a dual mechanism of action. First, they work to change the perception of pain in the brain and then increase the pain threshold in the spinal cord. By targeting both mechanisms, exogenous opioids can provide effective pain relief for individuals.<xref ref-type="bibr" rid="article-131364.r7">[7]</xref></p>
        <p>Physicochemical properties, such as lipid solubility and fraction un-ionized, play a significant role in determining the distribution of drugs in the body and their rate of access to the biophase where drug receptors are located. The pharmacokinetic and pharmacodynamic properties of opioids belonging to the fentanyl group, methadone, and morphine are essential considerations due to their distinctive features. Alfentanil and remifentanil exhibit relatively short equilibration half-lives of approximately 1 minute between plasma and the effect site. In comparison, fentanyl and sufentanil have longer equilibration half-lives of nearly 6 minutes.&#x000a0;Methadone has a relatively short half-life of approximately 8 minutes. However, among opioids, morphine&#x000a0;exhibits a longer equilibration half-life of 2 to 3 hours, whereas morphine-6-glucuronide (M6G) demonstrates the slowest plasma-effect site transfer, with an equilibration half-life of approximately 7 hours.<xref ref-type="bibr" rid="article-131364.r9">[9]</xref><bold>&#x000a0;</bold></p>
        <p>Morphine milligram equivalents (MME) serve as a measure to assess the relative potency and safety of opioids for pain management.<xref ref-type="bibr" rid="article-131364.r10">[10]</xref>&#x000a0;According to the&#x000a0;CDC (Centers for Disease Control &#x00026; Prevention) guidelines for opioids,&#x000a0;clinicians should exercise caution when converting methadone doses due to pharmacokinetic alterations. The absorption of transdermal fentanyl can be influenced by factors such as heat and other considerations. Buprenorphine, being a partial agonist, does not follow MME conversion guidelines. The use of MME should be approached cautiously, considering the potential variations in pharmacogenetics.<xref ref-type="bibr" rid="article-131364.r11">[11]</xref></p>
        <p>
<bold>Cannabis&#x000a0;</bold>
</p>
        <p>Similar to opioids, endocannabinoids are synthesized physiologically and released in the body by synapses to act on the cannabinoid receptors present on presynaptic endings. They perform the following essential&#x000a0;actions related to pain modulation:<xref ref-type="bibr" rid="article-131364.r12">[12]</xref><xref ref-type="bibr" rid="article-131364.r13">[13]</xref><xref ref-type="bibr" rid="article-131364.r14">[14]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Decrease the release of neurotransmitters.</p>
          </list-item>
          <list-item>
            <p>Activate descending inhibitory pain pathways.</p>
          </list-item>
          <list-item>
            <p>Reduce postsynaptic sensitivity and alleviate neural inflammation</p>
          </list-item>
          <list-item>
            <p>Modulate CB1 receptors&#x000a0;within central&#x000a0;nociception&#x000a0;processing areas and the spinal cord, which results in analgesic effects.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Attenuate inflammation through the activation of CB2 receptors.</p>
          </list-item>
        </list>
        <p>Marijuana is a dried mixture of extracts derived from the cannabis plant.&#x000a0;It is essential to understand the difference between cannabis, cannabinoids, and cannabidiol (CBD). Cannabis is typically&#x000a0;used to refer to products obtained from the <italic toggle="yes">Cannabis sativa</italic> plant.<xref ref-type="bibr" rid="article-131364.r15">[15]</xref>&#x000a0;Cannabinoids are extracted from the cannabis plants.&#x000a0;Specific cannabinoid-based treatments, which include nabilone, dronabinol, and CBD, have gained approval as medical interventions for&#x000a0;specific indications. CBD is a non-psychoactive component found in the cannabis plant, whereas 9-tetrahydrocannabinol (THC)&#x000a0;is the primary psychoactive component found in cannabis.<xref ref-type="bibr" rid="article-131364.r16">[16]</xref></p>
        <p>The pharmacokinetic properties of marijuana vary depending on its route of administration. Pulmonary inhalation of marijuana through the lungs rapidly causes a maximum plasma concentration within minutes. Subsequently, psychiatric effects begin within seconds to a few minutes after inhalation, peak after 15 to 30 minutes, and then gradually diminish over the course of 2 to 3 hours. On the other hand, oral ingestion of marijuana causes psychiatric effects that typically occur between 30 and 90 minutes. The effects reach their maximum after 2 to 3 hours and last about 4 to 12 hours.<xref ref-type="bibr" rid="article-131364.r17">[17]</xref></p>
      </sec>
      <sec id="article-131364.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Opioids</bold>
</p>
        <p>One of the primary concerns with opioid use for pain management is the risk of&#x000a0;drug abuse and addiction. This often involves the damage of the glutaminergic and dopaminergic pathways in the brain.<xref ref-type="bibr" rid="article-131364.r18">[18]</xref><xref ref-type="bibr" rid="article-131364.r19">[19]</xref>&#x000a0;The signs of opioid addiction include compulsive drug-seeking behavior, continued drug use despite adverse social and physical consequences, drug cravings, and withdrawal symptoms.<xref ref-type="bibr" rid="article-131364.r20">[20]</xref>&#x000a0;Importantly, opioid use disorder is one of the leading causes of drug-related deaths in the United States.<xref ref-type="bibr" rid="article-131364.r21">[21]</xref> Treating opioid addiction requires significant resources and can be prone to relapse, making it a complex and challenging endeavor.<xref ref-type="bibr" rid="article-131364.r22">[22]</xref><xref ref-type="bibr" rid="article-131364.r23">[23]</xref></p>
        <p>Furthermore, there are other adverse effects of opioid use, in addition to the risk of addiction, including immunosuppression, obesity, respiratory depression, constipation, and miosis.<xref ref-type="bibr" rid="article-131364.r7">[7]</xref><xref ref-type="bibr" rid="article-131364.r24">[24]</xref> While patients may develop tolerance to most of these adverse effects over time, miosis and constipation may persist and require supportive treatment during opioid therapy for pain management.<xref ref-type="bibr" rid="article-131364.r25">[25]</xref>&#x000a0;There are also more severe adverse effects associated with opioid use, such as opioid-induced hyperalgesia and narcotic bowel syndrome.<xref ref-type="bibr" rid="article-131364.r26">[26]</xref>&#x000a0;Discontinuing opioids in individuals with a dependence can lead to abstinence syndrome, a collection of unpleasant symptoms prevalent among the pediatric age group.<xref ref-type="bibr" rid="article-131364.r27">[27]</xref>&#x000a0;All of these factors raise issues of concern about opioid use for pain management.&#x000a0;</p>
        <p>The significant association between addiction and withdrawal can lead to various physical and psychological effects. In individuals with addiction issues, differentiating between chronic pain stemming from other causes and pain resulting from withdrawal can be challenging. However, certain symptoms, such as yawning, sweating, lacrimation, and piloerection, are more strongly associated with drug withdrawal rather than the pain caused by&#x000a0;other conditions.&#x000a0;Opioid withdrawal can&#x000a0;exacerbate baseline pain caused by other disorders. In the case of withdrawal from short-acting opioids, the duration is typically brief. This is why physical symptoms peak&#x000a0;in intensity&#x000a0;within 36 to 72 hours and then diminish in severity.<xref ref-type="bibr" rid="article-131364.r28">[28]</xref>&#x000a0;The&#x000a0;use of opioids during pregnancy can have serious consequences, including the development of Neonatal Opioid Withdrawal Syndrome (NOWS) in infants. NOWS is a potentially life-threatening condition characterized by withdrawal symptoms in newborns exposed to opioids during gestation.<xref ref-type="bibr" rid="article-131364.r29">[29]</xref><xref ref-type="bibr" rid="article-131364.r30">[30]</xref>&#x000a0;</p>
        <p>
<bold>Cannabis</bold>
</p>
        <p>Cannabis has faced significant restrictions primarily due to its psychotropic effect,&#x000a0;often associated with recreational use and the resulting social stigma. As a result, cannabis remains illegal in numerous countries and is classified as a Schedule I status in the United States. Furthermore, cannabis cultivation and production have been prohibited for nearly 75 years, creating barriers to conducting comprehensive research and inhibiting its potential medical applications.<xref ref-type="bibr" rid="article-131364.r31">[31]</xref>&#x000a0;Cannabinoids can cause various short-term effects, but tolerance to these effects can develop over time.<xref ref-type="bibr" rid="article-131364.r32">[32]</xref><xref ref-type="bibr" rid="article-131364.r33">[33]</xref>&#x000a0;The long-term effects of cannabis are more difficult to evaluate as they primarily stem from recreational use.<xref ref-type="bibr" rid="article-131364.r32">[32]</xref>&#x000a0;Cannabis is generally better tolerated than oral cannabinoids.<xref ref-type="bibr" rid="article-131364.r34">[34]</xref>&#x000a0;However, there is limited data available regarding the efficacy of cannabinoids in treating pain and whether they can serve as a safe substitute for opioids.<xref ref-type="bibr" rid="article-131364.r35">[35]</xref>&#x000a0;Cannabis use disorder (CUD) is a significant and often underestimated risk associated with cannabis use, affecting approximately 10% of the 193 million cannabis users worldwide. The addictive potential of cannabis is often underestimated, despite its widespread use as a psychotropic substance. CUD is one of the leading causes of addiction in adolescents.<xref ref-type="bibr" rid="article-131364.r36">[36]</xref><xref ref-type="bibr" rid="article-131364.r37">[37]</xref><xref ref-type="bibr" rid="article-131364.r38">[38]</xref></p>
        <p>The psychoactive compound THC, found in cannabis, has been associated with various health concerns, including cardiovascular disease, acute pancreatitis, cannabinoid hyperemesis syndrome, and lung disease when smoked.<xref ref-type="bibr" rid="article-131364.r39">[39]</xref><xref ref-type="bibr" rid="article-131364.r40">[40]</xref>&#x000a0;In addition, occupational injuries have been linked to its use. Furthermore, cannabis use during pregnancy has been associated with an increased risk of neonatal morbidity and death.<xref ref-type="bibr" rid="article-131364.r41">[41]</xref> Long-term cannabis use can have cognitive risks due to the attenuation of gray matter in the brain.<xref ref-type="bibr" rid="article-131364.r42">[42]</xref>&#x000a0;Psychopathological effects have also been reported with cannabis use, including schizophrenia, acute psychosis, depression, bipolar disorder, and anxiety.<xref ref-type="bibr" rid="article-131364.r43">[43]</xref>&#x000a0;However, patients using medical cannabis (MC), many of whom have chronic pain, have reported certain health benefits such as improved sleep and pain management.<xref ref-type="bibr" rid="article-131364.r44">[44]</xref>&#x000a0;The most common adverse drug reactions reported with CBD are&#x000a0;diarrhea, reduced appetite, and vomiting.<xref ref-type="bibr" rid="article-131364.r45">[45]</xref></p>
        <p>The drug interactions of opioids are widely known, and it is essential to exercise vigilance regarding the potential drug interactions of cannabis.<xref ref-type="bibr" rid="article-131364.r46">[46]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Warfarin: THC and CBD can inhibit the metabolism of warfarin by inhibiting CYP2C9, potentially leading to supratherapeutic&#x000a0;INR.</p>
          </list-item>
          <list-item>
            <p>Clopidogrel: CBD can increase the levels of clopidogrel due to competitive inhibition of CYP2C19.</p>
          </list-item>
          <list-item>
            <p>P-glycoprotein substrates: CBD and THC can act as substrates and inhibitors of P-glycoprotein, potentially increasing the concentration of drugs such as digoxin and loperamide.</p>
          </list-item>
          <list-item>
            <p>Direct-acting oral anticoagulants (DOACs): CBD and THC can increase the plasma concentration of dabigatran, apixaban, and rivaroxaban by inhibiting P-glycoproteins and CYP3A4.</p>
          </list-item>
          <list-item>
            <p>Fexinidazole: Fexinidazole can inhibit CYP3A4 and may significantly increase the concentrations of CYP3A4 substrates, including cannabis.<xref ref-type="bibr" rid="article-131364.r47">[47]</xref></p>
          </list-item>
          <list-item>
            <p>Antiepileptic drugs: Concurrent use of CBD with valproate and clobazam can increase the risk of sedation and hepatotoxicity.<xref ref-type="bibr" rid="article-131364.r45">[45]</xref></p>
          </list-item>
          <list-item>
            <p>Sirolimus: P-glycoprotein inhibitors can&#x000a0;increase sirolimus concentrations and the risk for toxicities. Simultaneous use of P-glycoprotein inhibitors should be avoided.<xref ref-type="bibr" rid="article-131364.r48">[48]</xref><xref ref-type="bibr" rid="article-131364.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Tacrolimus: CBD can increase tacrolimus concentrations, especially at higher doses, due to CYP3A4 and P-glycoprotein inhibition. Caution is advised when using them together.<xref ref-type="bibr" rid="article-131364.r45">[45]</xref></p>
          </list-item>
        </list>
        <p>Chronic noncancer pain affects approximately 20% of adults. According to the CDC reports,&#x000a0;a 50-mg morphine equivalent dose (MED) increases the risk of lethal overdose compared to a 20-mg MED. The mortality risk further increases 10-fold for MED&#x000a0;exceeding 90 mg. In comparison, CBD has been shown to provide pain relief with fewer adverse reactions than opioids. A typical dosage of CBD for pain relief is around 5 mg twice daily, with a maximum recommended dosage of up to 40 mg daily. It is important to note that the CBD dosage used for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome is higher, typically ranging from 5&#x000a0;to 10 mg/kg per day, compared to the dosage used for pain relief.<xref ref-type="bibr" rid="article-131364.r50">[50]</xref></p>
      </sec>
      <sec id="article-131364.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Opioids</bold>
</p>
        <p>The second and third steps of the World Health Organization's step ladder for pain management involve the use of opioids.<xref ref-type="bibr" rid="article-131364.r51">[51]</xref>&#x000a0;Opioids commonly alleviate pain in gastrointestinal pathologies, such as chronic pancreatitis and inflammatory bowel disease.<xref ref-type="bibr" rid="article-131364.r52">[52]</xref>&#x000a0;They are also prescribed for osteoarthritis, migraine, lower back pain, cancer, and postoperative pain. The efficacy of opioids in managing these conditions has been proven through randomized clinical trials (RCT) for some of these conditions.<xref ref-type="bibr" rid="article-131364.r53">[53]</xref><xref ref-type="bibr" rid="article-131364.r54">[54]</xref><xref ref-type="bibr" rid="article-131364.r55">[55]</xref></p>
        <p>
<bold>Cannabinoids</bold>
</p>
        <p>Cannabis is currently not approved by the&#x000a0;United States Food and Drug Administration (FDA) and is considered an illicit drug by the US Drug Enforcement Agency (DEA). However, several US states have legalized its use&#x000a0;in certain medical conditions.<xref ref-type="bibr" rid="article-131364.r56">[56]</xref>&#x000a0;MC treats various conditions, including migraines, chronic pain, back pain, arthritic pain, and pain associated with cancer and surgery.<xref ref-type="bibr" rid="article-131364.r56">[56]</xref><xref ref-type="bibr" rid="article-131364.r57">[57]</xref> Multiple studies have indicated that patients undergoing pain treatment can effectively substitute their opioid medication with cannabis, potentially contributing to mitigating the opioid epidemic.<xref ref-type="bibr" rid="article-131364.r58">[58]</xref>&#x000a0;Cannabinoids also reduce neuropathic pain associated with different conditions and prevent diabetic neuropathic pain when administered early in the disease progression.<xref ref-type="bibr" rid="article-131364.r59">[59]</xref><xref ref-type="bibr" rid="article-131364.r60">[60]</xref>&#x000a0;In addition, cannabinoids also reduce inflammatory pain and thus can be used in conditions such as arthritis, sickle cell disease, cancer, and inflammatory bowel disease.<xref ref-type="bibr" rid="article-131364.r61">[61]</xref><xref ref-type="bibr" rid="article-131364.r62">[62]</xref></p>
        <p>Several studies have demonstrated that MC helps reduce the opioid dosage for patients undergoing treatment for non-cancer pain. It can also be substituted in place of opioids to achieve&#x000a0;therapeutic benefits.<xref ref-type="bibr" rid="article-131364.r63">[63]</xref><xref ref-type="bibr" rid="article-131364.r64">[64]</xref><xref ref-type="bibr" rid="article-131364.r65">[65]</xref>&#x000a0;This opioid-sparing effect of cannabinoids holds a significant value as it emphasizes the potential synergistic use of both modalities, rather than relying exclusively on a single treatment approach, to achieve optimal outcomes.</p>
        <p>Several cannabinoids are available, including CBD, dronabinol, and nabilone, each with specific indications.&#x000a0;CBD has been approved for treating refractory seizures in patients with Lennox-Gastaut syndrome, tuberous sclerosis, and Dravet syndrome.<xref ref-type="bibr" rid="article-131364.r66">[66]</xref><xref ref-type="bibr" rid="article-131364.r67">[67]</xref><xref ref-type="bibr" rid="article-131364.r68">[68]</xref>&#x000a0;Dronabinol is primarily used to manage&#x000a0;anorexia associated with weight loss in patients with AIDS and for refractory nausea and vomiting associated with chemotherapy(CINV).&#x000a0;Nabilone is indicated for patients with refractory CINV.<xref ref-type="bibr" rid="article-131364.r69">[69]</xref><xref ref-type="bibr" rid="article-131364.r70">[70]</xref>&#x000a0;The increasing use of cannabis-based&#x000a0;therapeutics in sports medicine among athletes is due to their potential to modulate neuropathic, inflammatory, and central pain with reduced adverse effects compared to opioids.<xref ref-type="bibr" rid="article-131364.r71">[71]</xref></p>
      </sec>
      <sec id="article-131364.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>Marijuana use can lead to various symptoms and effects if used by an inexperienced user in large doses. These symptoms can include anxiety, paranoia, depersonalization, depressed mood, illusions, and hallucinations. In addition, studies have shown that marijuana use can affect blood flow to the temporal lobe of the brain in smokers.<xref ref-type="bibr" rid="article-131364.r72">[72]</xref>&#x000a0;Furthermore, there is a concern that marijuana use may serve as a gateway to the use of other potentially more dangerous narcotic drugs.<xref ref-type="bibr" rid="article-131364.r72">[72]</xref>&#x000a0;</p>
        <p>According to The American Society of Regional Anesthesia and Pain Medicine (ASRA), smoking cannabis increases the risk of perioperative myocardial infarction and can harm airway resistance. As a precautionary measure, ASRA recommends delaying elective surgery for at least 2 hours after&#x000a0;smoking&#x000a0;cannabis.<xref ref-type="bibr" rid="article-131364.r46">[46]</xref></p>
        <p>Legal issues surrounding the use of cannabis have indeed hindered research progress and contributed to delays in fully understanding its potential benefits and risks. While some states and countries have legalized cannabis use for medical and recreational purposes, there are still significant variations in the legal status of cannabis across different regions.&#x000a0;</p>
        <p>Opioid use disorder has become an epidemic in the United States recently. In addition, respiratory depression associated with opioid use is one of the primary factors contributing to fatal overdoses, which has resulted&#x000a0;in a significant loss of lives. Given these challenges related to opioid use, there is a pressing need to find a safer and more effective alternative for pain management, particularly for patients with chronic and terminal diseases. This alternative should minimize the risks of drug misuse, dependence, and overdose while offering superior efficacy and a more favorable benefit-to-risk ratio than opioids.</p>
      </sec>
      <sec id="article-131364.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Chronic pain can significantly affect an individual's lifestyle due to its somatic and psychological effects. Therefore, optimal chronic pain management often requires a multidisciplinary approach involving healthcare professionals such as pain medicine specialists, internists, and psychiatrists. This condition is addressed well by using potent analgesics, including opioids, which can provide effective pain relief. However, it is essential to closely monitor patients by scheduling regular follow-up visits to assess their response to treatment, address any emerging adverse effects, and make necessary adjustments in dosage as needed. For accurate conversion and appropriate dosing of opioids, pharmacists should be consulted as they possess the expertise to provide precise dosing information for the prescribed medications and perform medication reconciliation to prevent potential drug interactions. Moreover, due to the potentially fatal effects of opioids, patients should be thoroughly educated about the adverse signs and symptoms associated with opioid use and the potential for drug abuse and dependence.</p>
        <p>Nurses are vital in monitoring patients for respiratory depression, a potential adverse effect of opioid use. Pain management specialists are responsible for monitoring and managing the patient's pain and ensuring the accurate dosing of prescribed medications. They utilize various tools (such as clinical examinations) and validated questionnaires (such as the Pain Assessment in Advanced Dementia (PAINAD) or the Dallas pain questionnaire for back pain) to evaluate the severity and characteristics of pain in patients.<xref ref-type="bibr" rid="article-131364.r73">[73]</xref>&#x000a0;Pharmacists are responsible for accurately dosing prescribed medications, including opioids, CBD, dronabinol, and nabilone. In the case of opioid overdose, the involvement of critical care physicians and emergency medicine clinicians plays a&#x000a0;crucial&#x000a0;role.</p>
        <p>The incidence of CBD toxicity has been reportedly increasing; therefore, it is recommended to consult the Poison Control Center or a medical toxicologist for the latest information and guidance in cases of suspected toxicity.<xref ref-type="bibr" rid="article-131364.r74">[74]</xref>&#x000a0;In the perioperative period, anesthetists play a crucial role in caring for patients with cannabis use disorder. An interprofessional team approach involving clinicians (such as physicians, nurses, nurse practitioners, and physician assistants), specialists, pharmacists, and toxicologists is highly beneficial in improving the outcomes related to cannabis and opioids for pain management and preventing adverse effects.</p>
      </sec>
      <sec id="article-131364.s8" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Pain is a common and chief complaint among patients in both ambulatory and hospital settings. Clinicians&#x000a0;effectively manage pain by obtaining&#x000a0;a thorough&#x000a0;history from the patient, conducting a comprehensive physical examination, investigating for accurate diagnosis appropriately, and incorporating evidence-based medicine for treating pain.<xref ref-type="bibr" rid="article-131364.r75">[75]</xref></p>
        <p>Healthcare professionals should&#x000a0;examine the etiology of pain in their patients. For&#x000a0;managing acute musculoskeletal pain and inflammation, healthcare professionals should consider prescribing NSAIDs as the initial pain relief approach before recommending opioids&#x000a0;or&#x000a0;cannabis to patients.<xref ref-type="bibr" rid="article-131364.r76">[76]</xref>&#x000a0;The American Gastroenterological Association guidelines suggest dicyclomine for&#x000a0;managing spasmodic pain associated with irritable&#x000a0;bowel syndrome. Intraarticular injection of corticosteroids is recommended for patients in cases of osteoarthritis.</p>
        <p>Fibromyalgia should be considered in patients exhibiting multiple tender points during a physical examination and with standard laboratory results. Regarding treatment, FDA-approved medications, such as duloxetine, pregabalin, and milnacipran, can be prescribed to help manage fibromyalgia symptoms.<xref ref-type="bibr" rid="article-131364.r77">[77]</xref>&#x000a0;</p>
        <p>The first-line medications for treating trigeminal neuralgia are carbamazepine and oxcarbazepine. Diabetic neuropathy or postherpetic neuralgia responds well to gabapentin medication.<xref ref-type="bibr" rid="article-131364.r78">[78]</xref>&#x000a0;If the pain is intractable and not responding to other treatment options, opioids or CBD may be considered.</p>
      </sec>
      <sec id="article-131364.s9" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>The healthcare team can monitor the&#x000a0;misuse&#x000a0;of cannabis and opioids using the prescription drug monitoring program (PDMP).<xref ref-type="bibr" rid="article-131364.r79">[79]</xref></p>
      </sec>
      <sec id="article-131364.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131364&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131364">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/131364/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=131364">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-131364.s11">
        <title>References</title>
        <ref id="article-131364.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <article-title>Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy.</article-title>
            <source>Pain Suppl</source>
            <year>1986</year>
            <volume>3</volume>
            <fpage>S1</fpage>
            <page-range>S1-226</page-range>
            <pub-id pub-id-type="pmid">3461421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>What is pain?</article-title>
            <source>J Am Vet Med Assoc</source>
            <year>2002</year>
            <month>Jul</month>
            <day>15</day>
            <volume>221</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <page-range>202-5</page-range>
            <pub-id pub-id-type="pmid">12118579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woolf</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>What is this thing called pain?</article-title>
            <source>J Clin Invest</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>120</volume>
            <issue>11</issue>
            <fpage>3742</fpage>
            <page-range>3742-4</page-range>
            <pub-id pub-id-type="pmid">21041955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loeser</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Melzack</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pain: an overview.</article-title>
            <source>Lancet</source>
            <year>1999</year>
            <month>May</month>
            <day>08</day>
            <volume>353</volume>
            <issue>9164</issue>
            <fpage>1607</fpage>
            <page-range>1607-9</page-range>
            <pub-id pub-id-type="pmid">10334273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manjiani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Kunnumpurath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Vadivelu</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Availability and utilization of opioids for pain management: global issues.</article-title>
            <source>Ochsner J</source>
            <year>2014</year>
            <season>Summer</season>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>208</fpage>
            <page-range>208-15</page-range>
            <pub-id pub-id-type="pmid">24940131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okusanya</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Asaolu</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Ehiri</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kimaru</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Okechukwu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosales</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review.</article-title>
            <source>Syst Rev</source>
            <year>2020</year>
            <month>Jul</month>
            <day>28</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>167</fpage>
            <pub-id pub-id-type="pmid">32723354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Current research on opioid receptor function.</article-title>
            <source>Curr Drug Targets</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-46</page-range>
            <pub-id pub-id-type="pmid">22204322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of opioids.</article-title>
            <source>Pharmacol Rev</source>
            <year>1983</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <page-range>283-323</page-range>
            <pub-id pub-id-type="pmid">6144112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;tsch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic-pharmacodynamic modeling of opioids.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2005</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5 Suppl</issue>
            <fpage>S90</fpage>
            <page-range>S90-103</page-range>
            <pub-id pub-id-type="pmid">15907650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Urman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Labeling Morphine Milligram Equivalents on Opioid Packaging: a Potential Patient Safety Intervention.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>May</month>
            <day>31</day>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">29855852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ragan</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2022</year>
            <month>Nov</month>
            <day>04</day>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>1</fpage>
            <page-range>1-95</page-range>
            <pub-id pub-id-type="pmid">36327391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manzanares</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carrascosa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>239</fpage>
            <page-range>239-57</page-range>
            <pub-id pub-id-type="pmid">18615144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rice</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Farquhar-Smith</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy.</article-title>
            <source>Prostaglandins Leukot Essent Fatty Acids</source>
            <year>2002</year>
            <season>Feb-Mar</season>
            <volume>66</volume>
            <issue>2-3</issue>
            <fpage>243</fpage>
            <page-range>243-56</page-range>
            <pub-id pub-id-type="pmid">12052040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anthony</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Rahmat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sangle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoid Receptors and Their Relationship With Chronic Pain: A Narrative Review.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Sep</month>
            <day>14</day>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>e10436</fpage>
            <pub-id pub-id-type="pmid">33072446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Gamaldo</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions.</article-title>
            <source>J Clin Neurophysiol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-49</page-range>
            <pub-id pub-id-type="pmid">31895189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Cannabidiol</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">31644197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grotenhermen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of cannabinoids.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2003</year>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-60</page-range>
            <pub-id pub-id-type="pmid">12648025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunha-Oliveira</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rego</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs.</article-title>
            <source>Brain Res Rev</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>192</fpage>
            <page-range>192-208</page-range>
            <pub-id pub-id-type="pmid">18440072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LaLumiere</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Kalivas</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Glutamate release in the nucleus accumbens core is necessary for heroin seeking.</article-title>
            <source>J Neurosci</source>
            <year>2008</year>
            <month>Mar</month>
            <day>19</day>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>3170</fpage>
            <page-range>3170-7</page-range>
            <pub-id pub-id-type="pmid">18354020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ivanov</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Palmero</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Newcorn</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Neurorobiology and evidence-based biological treatments for substance abuse disorders.</article-title>
            <source>CNS Spectr</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>864</fpage>
            <page-range>864-77</page-range>
            <pub-id pub-id-type="pmid">17075558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dydyk</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Opioid Use Disorder</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">31985959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birnbaum</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vallow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schein</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.</article-title>
            <source>Clin J Pain</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>667</fpage>
            <page-range>667-76</page-range>
            <pub-id pub-id-type="pmid">16988561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verthein</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Krausz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schafer</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Association of personality disorders, family conflicts and treatment with quality of life in opiate addiction.</article-title>
            <source>Eur Addict Res</source>
            <year>2008</year>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-46</page-range>
            <pub-id pub-id-type="pmid">18182771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Candiotti</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gitlin</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?</article-title>
            <source>Curr Med Res Opin</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>1677</fpage>
            <page-range>1677-84</page-range>
            <pub-id pub-id-type="pmid">20465361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dumas</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.</article-title>
            <source>AAPS J</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>537</fpage>
            <page-range>537-51</page-range>
            <pub-id pub-id-type="pmid">18989788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szigethy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Knisely</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drossman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Opioid misuse in gastroenterology and non-opioid management of abdominal pain.</article-title>
            <source>Nat Rev Gastroenterol Hepatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>168</fpage>
            <page-range>168-180</page-range>
            <pub-id pub-id-type="pmid">29139482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Perez-Montejano</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Opioid neonatal abstinence syndrome: controversies and implications for practice.</article-title>
            <source>Curr Drug Abuse Rev</source>
            <year>2014</year>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-58</page-range>
            <pub-id pub-id-type="pmid">25323126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenblum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marsch</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Portenoy</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Opioids and the treatment of chronic pain: controversies, current status, and future directions.</article-title>
            <source>Exp Clin Psychopharmacol</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>405</fpage>
            <page-range>405-16</page-range>
            <pub-id pub-id-type="pmid">18837637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weller</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Crist</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Berrettini</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Neonatal Opioid Withdrawal Syndrome (NOWS): A Transgenerational Echo of the Opioid Crisis.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>11</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">32229609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leyenaar</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Moen</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>O'Malley</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Infant Mortality Associated With Prenatal Opioid Exposure.</article-title>
            <source>JAMA Pediatr</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>175</volume>
            <issue>7</issue>
            <fpage>706</fpage>
            <page-range>706-714</page-range>
            <pub-id pub-id-type="pmid">33843963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSohly</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Radwan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gul</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Phytochemistry of Cannabis sativa L.</article-title>
            <source>Prog Chem Org Nat Prod</source>
            <year>2017</year>
            <volume>103</volume>
            <fpage>1</fpage>
            <page-range>1-36</page-range>
            <pub-id pub-id-type="pmid">28120229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vu&#x0010d;kovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Srebro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vujovi&#x00107;</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Vu&#x0010d;eti&#x00107;</surname>
                <given-names>&#x0010c;</given-names>
              </name>
              <name>
                <surname>Prostran</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoids and Pain: New Insights From Old Molecules.</article-title>
            <source>Front Pharmacol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>1259</fpage>
            <pub-id pub-id-type="pmid">30542280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Collet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of medical cannabinoids: a systematic review.</article-title>
            <source>CMAJ</source>
            <year>2008</year>
            <month>Jun</month>
            <day>17</day>
            <volume>178</volume>
            <issue>13</issue>
            <fpage>1669</fpage>
            <page-range>1669-78</page-range>
            <pub-id pub-id-type="pmid">18559804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romero-Sandoval</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kolano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Alvarado-V&#x000e1;zquez</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Cannabis and Cannabinoids for Chronic Pain.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2017</year>
            <month>Oct</month>
            <day>05</day>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>67</fpage>
            <pub-id pub-id-type="pmid">28983880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sabioni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trigo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Betz-Stablein</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Murnion</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lintzeris</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khor</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Foll</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>9</issue>
            <fpage>1752</fpage>
            <page-range>1752-1765</page-range>
            <pub-id pub-id-type="pmid">28327548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashemi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cannabis Use Disorder in Adolescents.</article-title>
            <source>Child Adolesc Psychiatr Clin N Am</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-20</page-range>
            <pub-id pub-id-type="pmid">36410900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connor</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Stjepanovi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Foll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hoch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Budney</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Cannabis use and cannabis use disorder.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2021</year>
            <month>Feb</month>
            <day>25</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">33627670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zehra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Manza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiers</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Volkow</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Cannabis Addiction and the Brain: a Review.</article-title>
            <source>J Neuroimmune Pharmacol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>438</fpage>
            <page-range>438-452</page-range>
            <pub-id pub-id-type="pmid">29556883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boehnke</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Litinas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clauw</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain.</article-title>
            <source>J Pain</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>739</fpage>
            <page-range>739-44</page-range>
            <pub-id pub-id-type="pmid">27001005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>The Cannabis Dilemma: A Review of Its Associated Risks and Clinical Efficacy.</article-title>
            <source>J Addict</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>707596</fpage>
            <pub-id pub-id-type="pmid">26539302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metz</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Allshouse</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Hogue</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Goldenberg</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Varner</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Saade</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>217</volume>
            <issue>4</issue>
            <fpage>478.e1</fpage>
            <page-range>478.e1-478.e8</page-range>
            <pub-id pub-id-type="pmid">28578174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nader</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults.</article-title>
            <source>Am J Drug Alcohol Abuse</source>
            <year>2018</year>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-18</page-range>
            <pub-id pub-id-type="pmid">28498718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schatman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cannabis for Chronic Pain: Not Ready for Prime Time.</article-title>
            <source>Am J Public Health</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>109</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-51</page-range>
            <pub-id pub-id-type="pmid">32941762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piper</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Beals</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Abess</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Cobb</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>DeKeuster</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Chronic pain patients' perspectives of medical cannabis.</article-title>
            <source>Pain</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>158</volume>
            <issue>7</issue>
            <fpage>1373</fpage>
            <page-range>1373-1379</page-range>
            <pub-id pub-id-type="pmid">28328576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu-Sawwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scutt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Emerging Use of Epidiolex (Cannabidiol) in Epilepsy.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>485</fpage>
            <page-range>485-499</page-range>
            <pub-id pub-id-type="pmid">32839652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwenk</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Sondekoppam</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zakowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rzasa-Lynn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hooten</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viscusi</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Narouze</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids.</article-title>
            <source>Reg Anesth Pain Med</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>97</fpage>
            <page-range>97-117</page-range>
            <pub-id pub-id-type="pmid">36596580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alshammari</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Alqahtani</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Alanazi</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kamal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jawaid</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ghoneim</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Alshehri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shakeel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2022</year>
            <month>Jan</month>
            <day>21</day>
            <volume>15</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35215241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hartford</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kocherginsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eaton</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Zha</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nallari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maitland</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Fox-Kay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moshier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>House</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Undevia</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Gajewski</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Ratain</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.</article-title>
            <source>Clin Cancer Res</source>
            <year>2012</year>
            <month>Sep</month>
            <day>01</day>
            <volume>18</volume>
            <issue>17</issue>
            <fpage>4785</fpage>
            <page-range>4785-93</page-range>
            <pub-id pub-id-type="pmid">22872575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000e1;zquez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guevara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guido</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Schaiquevich</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain.</article-title>
            <source>Biomed Res Int</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>3902740</fpage>
            <pub-id pub-id-type="pmid">32855964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacCallum</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Eadie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Boivin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain.</article-title>
            <source>Front Pharmacol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>633168</fpage>
            <pub-id pub-id-type="pmid">33995035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Araujo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pezonaga</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Borque</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>[Treatment of pain in the oncology patient].</article-title>
            <source>An Sist Sanit Navar</source>
            <year>2004</year>
            <volume>27 Suppl 3</volume>
            <fpage>63</fpage>
            <page-range>63-75</page-range>
            <pub-id pub-id-type="pmid">15723106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chatila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Al-Hanayneh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wadhwa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Parupudi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hernandez-Barco</surname>
                <given-names>YG</given-names>
              </name>
            </person-group>
            <article-title>Rising Prevalence of Opioid Use Disorder and Predictors for Opioid Use Disorder Among Hospitalized Patients With Chronic Pancreatitis.</article-title>
            <source>Pancreas</source>
            <year>2019</year>
            <season>Nov/Dec</season>
            <volume>48</volume>
            <issue>10</issue>
            <fpage>1386</fpage>
            <page-range>1386-1392</page-range>
            <pub-id pub-id-type="pmid">31688606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nalamachu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>An overview of pain management: the clinical efficacy and value of treatment.</article-title>
            <source>Am J Manag Care</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>14 Suppl</issue>
            <fpage>s261</fpage>
            <page-range>s261-6</page-range>
            <pub-id pub-id-type="pmid">24494608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzgibbon</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Clinical use of opioids for cancer pain.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-8</page-range>
            <pub-id pub-id-type="pmid">17686387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballantyne</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of opioids for chronic pain: a review of the evidence.</article-title>
            <source>Clin J Pain</source>
            <year>2008</year>
            <season>Jul-Aug</season>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>469</fpage>
            <page-range>469-78</page-range>
            <pub-id pub-id-type="pmid">18574357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stucke</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures.</article-title>
            <source>Ann Surg</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>265</volume>
            <issue>4</issue>
            <fpage>709</fpage>
            <page-range>709-714</page-range>
            <pub-id pub-id-type="pmid">27631771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosten</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>The neurobiology of opioid dependence: implications for treatment.</article-title>
            <source>Sci Pract Perspect</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-20</page-range>
            <pub-id pub-id-type="pmid">18567959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corroon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mischley</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cannabis as a substitute for prescription drugs - a cross-sectional study.</article-title>
            <source>J Pain Res</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>989</fpage>
            <page-range>989-998</page-range>
            <pub-id pub-id-type="pmid">28496355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats.</article-title>
            <source>Pain</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>105</volume>
            <issue>1-2</issue>
            <fpage>275</fpage>
            <page-range>275-83</page-range>
            <pub-id pub-id-type="pmid">14499445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsieh</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chandran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hooker</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>CZ</given-names>
              </name>
              <name>
                <surname>Salyers</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Wensink</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Honore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Central and peripheral sites of action for CB&#x02082; receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats.</article-title>
            <source>Br J Pharmacol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>162</volume>
            <issue>2</issue>
            <fpage>428</fpage>
            <page-range>428-40</page-range>
            <pub-id pub-id-type="pmid">20880025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turcotte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blanchet</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Laviolette</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flamand</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The CB<sub>2</sub> receptor and its role as a regulator of inflammation.</article-title>
            <source>Cell Mol Life Sci</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>73</volume>
            <issue>23</issue>
            <fpage>4449</fpage>
            <page-range>4449-4470</page-range>
            <pub-id pub-id-type="pmid">27402121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vincent</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.</article-title>
            <source>Haematologica</source>
            <year>2016</year>
            <month>May</month>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>566</fpage>
            <page-range>566-77</page-range>
            <pub-id pub-id-type="pmid">26703965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barlowe</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Koliani-Pace</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>Effects of Medical Cannabis on Use of Opioids and Hospital Visits by Patients With Painful Chronic Pancreatitis.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>2608</fpage>
            <page-range>2608-2609.e1</page-range>
            <pub-id pub-id-type="pmid">30664949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Jikomes</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Medical cannabis patterns of use and substitution for opioids &#x00026; other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients.</article-title>
            <source>Harm Reduct J</source>
            <year>2019</year>
            <month>Jan</month>
            <day>28</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <pub-id pub-id-type="pmid">30691503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vigil</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Stith</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Reeve</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>e0187795</fpage>
            <pub-id pub-id-type="pmid">29145417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golub</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2021</year>
            <volume>1264</volume>
            <fpage>93</fpage>
            <page-range>93-110</page-range>
            <pub-id pub-id-type="pmid">33332006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devinsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Laux</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>S</given-names>
              </name>
              <collab>Cannabidiol in Dravet Syndrome Study Group</collab>
            </person-group>
            <article-title>Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>25</day>
            <volume>376</volume>
            <issue>21</issue>
            <fpage>2011</fpage>
            <page-range>2011-2020</page-range>
            <pub-id pub-id-type="pmid">28538134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bebin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Bhathal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Kotulska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sahebkar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Checketts</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Knappertz</surname>
                <given-names>V</given-names>
              </name>
              <collab>GWPCARE6 Study Group</collab>
            </person-group>
            <article-title>Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.</article-title>
            <source>JAMA Neurol</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-292</page-range>
            <pub-id pub-id-type="pmid">33346789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r69">
          <label>69</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dean</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Dronabinol Therapy and <italic>CYP2C9</italic> Genotype</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kattman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <source>Medical Genetics Summaries [Internet]</source>
            <publisher-name>National Center for Biotechnology Information (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>11</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">33211456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pagano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Navarra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Avilia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bifulco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laezza</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoids: Therapeutic Use in Clinical Practice.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Mar</month>
            <day>19</day>
            <volume>23</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">35328765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Schleich</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Slayman</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Marcussen</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Understanding Cannabis-Based Therapeutics in Sports Medicine.</article-title>
            <source>Sports Health</source>
            <year>2020</year>
            <season>Nov/Dec</season>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>540</fpage>
            <page-range>540-546</page-range>
            <pub-id pub-id-type="pmid">32936058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r72">
          <label>72</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Joy</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <source>Marijuana as Medicine? The Science Beyond the Controversy</source>
            <publisher-name>National Academies Press (US)</publisher-name>
            <publisher-loc>Washington (DC)</publisher-loc>
            <year>2000</year>
            <pub-id pub-id-type="pmid">25077214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warden</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Volicer</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale.</article-title>
            <source>J Am Med Dir Assoc</source>
            <year>2003</year>
            <season>Jan-Feb</season>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-15</page-range>
            <pub-id pub-id-type="pmid">12807591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Otten</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of cannabidiol related cases reported in the National Poison Data System - 2019-2020.</article-title>
            <source>Am J Emerg Med</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>48</volume>
            <fpage>218</fpage>
            <page-range>218-223</page-range>
            <pub-id pub-id-type="pmid">33975134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huygen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kallewaard</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>van Tulder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Boxem</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vissers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Kleef</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Zundert</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>"Evidence-Based Interventional Pain Medicine According to Clinical Diagnoses": Update 2018.</article-title>
            <source>Pain Pract</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>664</fpage>
            <page-range>664-675</page-range>
            <pub-id pub-id-type="pmid">30957944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorlund</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Simic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pihl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berthelsen</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Juhl</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Similar Effects of Exercise Therapy, Nonsteroidal Anti-inflammatory Drugs, and Opioids for Knee Osteoarthritis Pain: A Systematic Review with Network Meta-analysis.</article-title>
            <source>J Orthop Sports Phys Ther</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>207</fpage>
            <page-range>207-216</page-range>
            <pub-id pub-id-type="pmid">35442752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farag</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Yunusa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goswami</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Doucette</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Eguale</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>May</month>
            <day>02</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>e2212939</fpage>
            <pub-id pub-id-type="pmid">35587348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sandroni</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Central Neuropathic Pain Syndromes.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>91</volume>
            <issue>3</issue>
            <fpage>372</fpage>
            <page-range>372-85</page-range>
            <pub-id pub-id-type="pmid">26944242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131364.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gazmararian</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality.</article-title>
            <source>J Opioid Manag</source>
            <year>2017</year>
            <season>Jul/Aug</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>229</fpage>
            <page-range>229-239</page-range>
            <pub-id pub-id-type="pmid">28953315</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
